June 12, 2018
Sciecure Pharma Inc. receives FDA approval for Paroxetine HCl Extended Release Tablets, 12.5 mg, 25 mg, and 37.5 mg, an AB rated generic version of Paxil CR.
September 28, 2017
Sciecure Pharma Inc. receives FDA approval for Budesonide capsules, 3 mg, an AB rated generic version of Entocort EC. According to IMS Health, the 2016 annual sales of Budesonide capsules, 3 mg were $296 million in the United States.
September 16, 2016
Sciecure Pharma Inc.’s Quality Control and Clinical Manufacturing Laboratories located at Monmouth Junction, New Jersey has successfully passed its first FDA inspection. This is a combined General cGMP and Pre-approval Inspections that lasted for a total of five days.
January 12, 2016
Yabao Pharmaceuticals and Sciecure Pharma Announce Strategic Partnership to Co-develop, Manufacture and Commercialize Generics for U.S. and China
Sciecure Pharma Inc. (Monmouth Junction, New Jersey) and Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351) today announced a strategic partnership to co-develop and commercialize high technological barrier generics medicines for both the U.S. and China markets.
Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Sciecure Pharma-developed products in China and to manufacture for both the U.S. and China markets, while Sciecure Pharma will retain rights to commercialize in U.S. and all other markets. Financial terms were not disclosed.
“Yabao is pleased to collaborate with Sciecure Pharma, a dynamic company with extensive drug development expertise and know-how on high technological barrier controlled release formulation, to synergize with Yabao’s cGMP manufacturing and leading commercialization capabilities in China.”, commented Dr. Peng Wang, President of R&D, Yabao Pharmaceutical Co., “Yabao is actively partnering with leading overseas companies to bring in and deliver high quality medicines with unmet needs in China. This partnership also demonstrates that Yabao’s competitive R&D and manufacturing have expanded into developed markets.”
“We are pleased to work with a leading Chinese pharma company like Yabao,” said Dr. Nuo (Nolan) Wang, CEO of Sciecure Pharma Inc., “With current stormy policy changes in the pharmaceutical sector in China, the demand for high quality pharmaceutical products is rapidly growing. Sciecure Pharma is uniquely positioned to meet such demand through strategic partnering. We trust our collaboration with Yabao will be synergistic and successful in quickly bringing high quality pharma products to patients in China.”
About Yabao Pharmaceutial Co.
Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China pharmaceutical company with fully integrated development, manufacturing, and commercialization capabilities. Yabao recently has been pursuing strategic development and commercialization partnerships to bring high quality innovative or generic medicines into China. In addition to strong clinical and regulatory capabilities, Yabao has extensive expertise in formulation and API production and meets current Good Manufacturing Practice (cGMP) requirements with two manufacturing sites approved by U.S. FDA and a European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit http://www.yabao.com.cn
Sciecure Pharma Inc. (Monmouth Junction, New Jersey) and Yabao Pharmaceutical Co, Inc. (Shanghai Stock Exchange 600351) today announced a strategic partnership to co-develop and commercialize high technological barrier generics medicines for both the U.S. and China markets.
Under the terms of the agreement, Yabao will exclusively own rights to commercialize certain Sciecure Pharma-developed products in China and to manufacture for both the U.S. and China markets, while Sciecure Pharma will retain rights to commercialize in U.S. and all other markets. Financial terms were not disclosed.
“Yabao is pleased to collaborate with Sciecure Pharma, a dynamic company with extensive drug development expertise and know-how on high technological barrier controlled release formulation, to synergize with Yabao’s cGMP manufacturing and leading commercialization capabilities in China.”, commented Dr. Peng Wang, President of R&D, Yabao Pharmaceutical Co., “Yabao is actively partnering with leading overseas companies to bring in and deliver high quality medicines with unmet needs in China. This partnership also demonstrates that Yabao’s competitive R&D and manufacturing have expanded into developed markets.”
“We are pleased to work with a leading Chinese pharma company like Yabao,” said Dr. Nuo (Nolan) Wang, CEO of Sciecure Pharma Inc., “With current stormy policy changes in the pharmaceutical sector in China, the demand for high quality pharmaceutical products is rapidly growing. Sciecure Pharma is uniquely positioned to meet such demand through strategic partnering. We trust our collaboration with Yabao will be synergistic and successful in quickly bringing high quality pharma products to patients in China.”
About Yabao Pharmaceutial Co.
Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China pharmaceutical company with fully integrated development, manufacturing, and commercialization capabilities. Yabao recently has been pursuing strategic development and commercialization partnerships to bring high quality innovative or generic medicines into China. In addition to strong clinical and regulatory capabilities, Yabao has extensive expertise in formulation and API production and meets current Good Manufacturing Practice (cGMP) requirements with two manufacturing sites approved by U.S. FDA and a European agency, respectively. For more information about Yabao Pharmaceutical Co., please visit http://www.yabao.com.cn
June 5, 2015
To: All employees, and venders, and business related companies.
Please be informed that Mr. Wu (William) Tian has no authority to act on behalf of Sciecure Pharma, Inc. Mr. Tian served as CEO of Sciecure Pharma, Inc. prior to September 4, 2014, but on that date he was replaced CEO of Sciecure Pharma, Inc. by Dr. Nuo (Nolan) Wang. Mr. Tian served as Chief Operating Officer of Sciecure Pharma, Inc. from September 4, 2014 until his resignation on March 23, 2015.
Please be informed that Mr. Wu (William) Tian has no authority to act on behalf of Sciecure Pharma, Inc. Mr. Tian served as CEO of Sciecure Pharma, Inc. prior to September 4, 2014, but on that date he was replaced CEO of Sciecure Pharma, Inc. by Dr. Nuo (Nolan) Wang. Mr. Tian served as Chief Operating Officer of Sciecure Pharma, Inc. from September 4, 2014 until his resignation on March 23, 2015.
